Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on EquityReturn on Sales

Innate Pharma (IPHA) Debt Ratio (2017 - 2025)

Historic Debt Ratio for Innate Pharma (IPHA) over the last 9 years, with Q2 2025 value amounting to 0.29.

  • Innate Pharma's Debt Ratio rose 2410.24% to 0.29 in Q2 2025 from the same period last year, while for Jun 2025 it was 0.05, marking a year-over-year increase of 852.22%. This contributed to the annual value of 0.28 for FY2024, which is 2255.84% up from last year.
  • According to the latest figures from Q2 2025, Innate Pharma's Debt Ratio is 0.29, which was up 2410.24% from 0.28 recorded in Q4 2024.
  • In the past 5 years, Innate Pharma's Debt Ratio registered a high of 0.29 during Q2 2025, and its lowest value of 0.06 during Q2 2021.
  • Moreover, its 5-year median value for Debt Ratio was 0.2 (2023), whereas its average is 0.2.
  • The largest annual percentage gain for Innate Pharma's Debt Ratio in the last 5 years was 16644.31% (2021), contrasted with its biggest fall of 972.45% (2021).
  • Innate Pharma's Debt Ratio (Quarter) stood at 0.17 in 2021, then grew by 22.87% to 0.2 in 2022, then rose by 12.03% to 0.23 in 2023, then grew by 22.56% to 0.28 in 2024, then rose by 4.21% to 0.29 in 2025.
  • Its Debt Ratio stands at 0.29 for Q2 2025, versus 0.28 for Q4 2024 and 0.23 for Q2 2024.